As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
8 Analysts have issued a Iterum Therapeutics Plc forecast:
8 Analysts have issued a Iterum Therapeutics Plc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.94 -0.94 |
-
|
|
| EBITDA | -17 -17 |
55%
55%
|
|
| EBIT (Operating Income) EBIT | -18 -18 |
53%
53%
|
|
| Net Profit | -24 -24 |
15%
15%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Iterum Therapeutics Plc is a pharmaceutical company which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. It operates through the Ireland and Unites States geographical segments. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.
| Head office | Ireland |
| CEO | Corey Fishman |
| Employees | 9 |
| Founded | 2015 |
| Website | www.iterumtx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


